The Effects of Sertraline on Depression in Parkinson's Disease (PD; PDD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01437189|
Recruitment Status : Unknown
Verified August 2011 by Wei Luo, Zhejiang University.
Recruitment status was: Recruiting
First Posted : September 20, 2011
Last Update Posted : September 20, 2011
|Condition or disease||Intervention/treatment||Phase|
|Depression Parkinson's Disease||Drug: Sertraline||Not Applicable|
Depression in PD is associated with more severe cognitive and functional impairments, a faster progression of illness, worse quality of life, increase mortality and higher burden for caregivers, when compare PD patients without depression. Depression accounts for approximately 40-50% in PD patients, which is also well known as a main factor impacting on health-related quality of life (HRQoL) in negative way in the context of PD and even their caregivers. In our previous cross-sectional study, the investigators have already studied the prevalence of depressive symptoms in PD patients and also have proved how depressive symptoms severely worsen HRQoL in PD patients in the area of the mainland China. In order to improve HRQoL of PD, some interventions, for example, taking some antidepressants to improve depression are urgently required. In addition, the investigators had already tested the validity and reliability of Chinese version of the 39-item Parkinson's disease questionnaire (PDQ-39) in mainland China, the paper about which already have been published in journal of Zhejiang university science B (biomedicine and biotechnology) already, therefore, the investigators can use the questionnaire of Chinese version of PDQ-39 to assess PD patients' quality of life.
Treatment of depression with antidepressant drugs is well established. In the last 20 years, the application of antidepressant has risen mainly due to the introduction of the selective serotonin reuptake inhibitors (SSRIs). These drugs are now the most commonly prescribed antidepressants in patients with depression in general. Regarding depression in the context of PD, a recent survey in the U.S. showed that 63% of the prescriptions for depression in PD were for SSRIs and only 7.5% for tricyclic antidepressants (TCAs). The preference of SSRIs over the older TCAs is supposedly based on their similar efficacy but better tolerability, especially when compared with tertiary amines, such as amitriptyline or imipramine. Sertraline is characterized by a low selectivity for serotonin relative to dopamine reuptake, suggesting a favorable efficacy profile. There was a randomized study pointing out that both sertraline and low-dose amitriptyline improved depressive symptoms in PD, and a significant benefit on quality of life was observed only with sertraline. Still, more studies are needed to demonstrate whether sertraline is effective to depression in PD patients. Further more, there is no trial about the efficacy and safety of sertraline on depression in PD in mainland China. It's necessary for us to initiate and conduct this trial in mainland China.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease|
|Study Start Date :||August 2011|
|Estimated Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||March 2013|
- Drug: Sertraline
Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.Other Name: Zoloft
- change from baseline in Hamilton Depression Rating Scale [ Time Frame: 8 weeks ]
- change from baseline in questionnaire of PDQ-39 [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01437189
|Contact: Wei Luo, PH.D&M.Demail@example.com|
|Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University||Recruiting|
|Hangzhou, Zhejiang, China, 310009|
|Contact: Wei Luo, PH.D&M.D 13757120109 firstname.lastname@example.org|
|Principal Investigator:||Wei Luo, PH.D&M.D||School of medcine, Zhejiang University|